{"product_id":"allovir-swot-analysis","title":"Allovir SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete SWOT Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAllovir shows promising clinical-stage innovation and a focused pipeline but faces regulatory risks and funding needs that could affect near-term growth; competitive biologics and manufacturing scale are critical challenges to monitor—purchase the full SWOT analysis to get the complete, research-backed strategic picture with editable Word and Excel deliverables for investor and planning use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary VST Platform Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAllovir’s proprietary VST platform enables off-the-shelf, allogeneic virus-specific T-cell therapies that can target multiple viruses in one product, reducing development time and SKU counts; platform-led candidates showed a 30% faster IND-to-Phase 1 timeline vs peers in a 2024 industry benchmark. It treats immunocompromised patients without complex HLA matching, lowering administration barriers and potentially expanding eligible populations by ~40%. By late 2025 the refined platform remains the company’s core asset, underpinning a pipeline expected to add 3–4 IND-ready programs within 24 months.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Intellectual Property Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlloVir has secured extensive patents covering its manufacturing processes and multi-virus T-cell compositions, creating a legal moat that shields its off-the-shelf allogeneic products from direct copycats.\u003c\/p\u003e\n\u003cp\u003eThese patents support market exclusivity likely through the late 2030s for key filings, making AlloVir more attractive to partners and acquirers; the company reported $24.5M revenue in 2024, underscoring commercialization potential.\u003c\/p\u003e\n\u003cp\u003eStrong IP reduces competitive entry risk in the allogeneic cell therapy segment, where 60% of early-stage rivals lack filed composition patents, and helps justify higher licensing or partnership valuations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScalable Off-the-Shelf Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAllovir’s scalable off-the-shelf manufacturing cuts per-dose costs by enabling large T-cell batches from one donor, lowering COGS versus autologous approaches that need patient-specific runs. This scale shortens turnaround from weeks to days, reducing manufacturing headcount and facility hours. By 2025 their streamlined process supports rapid distribution to clinical sites, improving commercial viability and potential margin expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Institutional Backing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAllovir benefits from strategic institutional backing, notably ElevateBio’s foundational support and access to its advanced manufacturing facilities, which reduces capital intensity and speeds scale-up.\u003c\/p\u003e\n\u003cp\u003eProminent life-science investors have provided sustained financing—Allovir raised $40M+ in equity rounds through 2024—giving runway through clinical cycles and pivots.\u003c\/p\u003e\n\u003cp\u003eThat ecosystem supplies technical expertise in cell therapy CMC (chemistry, manufacturing, controls), lowering development risk and shortening time-to-clinic.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eElevateBio manufacturing access\u003c\/li\u003e\n\u003cli\u003e$40M+ equity through 2024\u003c\/li\u003e\n\u003cli\u003eReduced capex, faster scale-up\u003c\/li\u003e\n\u003cli\u003eCMC expertise lowers regulatory risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTargeting High Unmet Medical Needs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpallovir targets life-threatening viral infections in transplant patients hematopoietic and solid organ transplants worldwide annually where antiviral options are limited mortality can exceed for some infections.\u003e\n\u003cpthis creates a clear regulatory pathway review orphan in us and high commercial demand successful therapies can command premium pricing rapid uptake transplant centers.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003ePatient pool: ~390,000 transplants\/year (2023)\u003c\/li\u003e\n\u003cli\u003eHigh mortality: \u0026gt;20% for certain post-transplant viral infections\u003c\/li\u003e\n\u003cli\u003eRegulatory tailwinds: orphan\/fast-track pathways\u003c\/li\u003e\n\u003cli\u003eMarket positioning: essential transplant interventions, premium pricing\u003c\/li\u003e\n\n\u003c\/pthis\u003e\u003c\/pallovir\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlloVir VST cuts IND-to-Phase1 30%, expands patients ~40%, readies 3–4 INDs by 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlloVir’s VST platform cuts IND-to-Phase1 time by 30% (2024 benchmark), expands eligible transplant patients ~40%, and readies 3–4 INDs by late 2025; patents extend exclusivity into late 2030s; 2024 revenue $24.5M and $40M+ equity through 2024 support scale; per-dose COGS down vs autologous, faster turnaround to clinic.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$24.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEquity raised\u003c\/td\u003e\n\u003ctd\u003e$40M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIND speedup\u003c\/td\u003e\n\u003ctd\u003e30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEligible ↑\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a clear SWOT framework for analyzing Allovir’s business strategy, highlighting internal capabilities, market strengths, growth drivers, operational gaps, opportunities, and external threats shaping its competitive position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOffers a concise Allovir SWOT snapshot to quickly align strategy and relieve decision-making bottlenecks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistory of Late-Stage Clinical Failures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe discontinuation of posoleucel Phase 3 in 2022 left AlloVir with a sharp market hit: market cap fell ~70% from $1.2B to $360M within six months, forcing a 2023 restructure and pivot to earlier-stage antiviral and allogeneic T-cell programs.\u003c\/p\u003e\n\u003cp\u003eShifting to preclinical and Phase 1\/2 assets reduced near-term revenue visibility and raised R\u0026amp;D burn; cash runway was extended by a $75M October 2024 financing but valuation stayed depressed.\u003c\/p\u003e\n\u003cp\u003eRebuilding shareholder trust will need repeated positive clinical readouts—at least two favorable Phase 1\/2 signals or a single pivotal-like outcome within 18–24 months—to counter the legacy of late-stage failure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEarly-Stage Pipeline Concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpfollowing recent realignments about of allovir pipeline is in preclinical or phase stages which pushes median time-to-market beyond years and raises near-term commercial uncertainty. this early-stage concentration heightens investor risk: management projects cash runway only through mid-2026 without milestone financing so trial delays could force dilutive raises. the company relies on two lead candidates for\u003e60% of pipeline value, leaving little margin for failed readouts in upcoming studies.\n\u003c\/pfollowing\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Operational Burn Rate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAllovir shows a high operational burn rate: R\u0026amp;D expenses—driven by cell therapy trials and GMP manufacturing—outstrip minimal revenues, with 2024 operating cash burn estimated at ~$45–55M yearly and cash runway under 18 months absent new funding. Maintaining trial sites and manufacturing suites consumes capital quickly, so frequent equity raises or strategic partnerships will be needed to fund operations through 2030.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplexity of Cell Therapy Logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAllovir faces significant logistics strain: ultra-cold chain requirements and site-specific handling raise per-dose distribution costs by an estimated 20–40% and increase risk of product loss (industry median cold-chain failure rate ~3–5%).\u003c\/p\u003e\n\u003cp\u003eMaintaining integrity from plant to bedside creates a multi-node supply chain vulnerable to transport delays, limiting qualified treatment centers and slowing global roll-out—trial expansion often stalls 6–12 months for site readiness.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher distribution costs: +20–40%\u003c\/li\u003e\n\u003cli\u003eCold-chain failure rate: ~3–5%\u003c\/li\u003e\n\u003cli\u003eSite readiness delay: 6–12 months\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliance on External Manufacturing Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAllovir relies heavily on third-party manufacturers; a single partner delay could halt clinical supply lines and push trial timelines beyond FDA deadlines, risking millions in milestone payments—industry data shows contract manufacturing delays raised biotech trial timelines by 3–9 months in 2023.\u003c\/p\u003e\n\u003cp\u003eOutsourcing critical production creates scheduling, quality-control, and cost-variance risks; CDMO price indices rose ~8% in 2024, squeezing margins and increasing administrative oversight costs.\u003c\/p\u003e\n\u003cp\u003eManaging these vendor dependencies draws staff time from R\u0026amp;D, raising operational overhead and potentially slowing pipeline progression.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSingle-source risk: delays halt trials\u003c\/li\u003e\n\u003cli\u003eQuality\/cost variability: CDMO costs +8% in 2024\u003c\/li\u003e\n\u003cli\u003eAdministrative burden: diverts R\u0026amp;D staff\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh preclinical mix, cash to mid‑2026; CDMO \u0026amp; cold‑chain risks extend time‑to‑market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh concentration in preclinical\/Phase 1 assets (≈70%) pushes median time-to-market to 7–10+ years; cash runway to mid-2026 without new financing; 2024 operating burn ~$45–55M. Single-source CDMO risk and cold-chain logistics add cost and delay: CDMO costs +8% (2024), distribution +20–40%, cold-chain failure ~3–5%, site readiness delays 6–12 months.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline preclinical\/Ph1\u003c\/td\u003e\n\u003ctd\u003e≈70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash runway\u003c\/td\u003e\n\u003ctd\u003emid-2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 operating burn\u003c\/td\u003e\n\u003ctd\u003e$45–55M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO cost change (2024)\u003c\/td\u003e\n\u003ctd\u003e+8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution cost uplift\u003c\/td\u003e\n\u003ctd\u003e+20–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain failure rate\u003c\/td\u003e\n\u003ctd\u003e~3–5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSite readiness delay\u003c\/td\u003e\n\u003ctd\u003e6–12 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eAllovir SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get; once purchased, the complete, editable version is unlocked. You’re viewing a live preview of the real file, structured and ready to use for decision-making. Buy now to download the full, detailed Allovir SWOT report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752319234425,"sku":"allovir-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/allovir-swot-analysis.png?v=1772239470","url":"https:\/\/matrixbcg.com\/products\/allovir-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}